Stem Cells For Amyotrophic Lateral Sclerosis (ALS)

Stem Cells for ALS

Stem Cells For Amyotrophic Lateral Sclerosis (ALS) at Regenamex

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive and debilitating neurodegenerative disorder that affects the nerve cells responsible for muscle control. While there is currently no cure for ALS, regenerative medicine offers a ray of hope, and Wharton’s Jelly Mesenchymal Stem Cells (WJ-MSCs) hold potential as a therapeutic option. At Regenamex, we provide an innovative and advanced treatment option using Expanded Wharton’s Jelly Mesenchymal Stem Cells to address ALS and potentially improve motor function at a cellular level.

Wharton’s Jelly Mesenchymal Stem Cells and Neuroprotection:

Wharton’s Jelly, found in the umbilical cord, is a rich source of potent Mesenchymal Stem Cells. These Expanded WJ-MSCs possess neuroprotective properties that make them a promising candidate for ALS treatment. WJ-MSCs can help protect nerve cells from further damage, potentially slowing down the progression of this devastating disease.

Cellular-Level Regeneration:

ALS involves the degeneration and loss of motor neurons, leading to muscle weakness and paralysis. The regenerative effects of WJ-MSCs can aid in the repair and renewal of damaged nerve cells. By promoting cellular regeneration, WJ-MSC therapy may contribute to the preservation of motor neuron function and potentially slow the disease’s progression.

Motor Function Support:

ALS leads to the progressive loss of muscle control, affecting voluntary movement. WJ-MSCs release growth factors and other neurotrophic factors that can support neural growth and potentially improve motor function, offering hope for enhanced functional outcomes.

Anti-Inflammatory Effects:

Inflammation in the nervous system is believed to play a role in ALS progression. WJ-MSCs have potent anti-inflammatory effects and can modulate the immune response in the nervous system. By reducing neuroinflammation, WJ-MSC therapy may alleviate symptoms and contribute to better motor function outcomes.

Enhanced Quality of Life:

While there is no cure for ALS, WJ-MSC therapy offers potential benefits in terms of neuroprotection, cellular regeneration, and motor function support. The reduction in motor neuron damage, enhanced neural function, and potential improvements in motor abilities may lead to a better quality of life for patients and their families, even in the presence of the disease.

Personalized Treatment Approach:

At Regenamex, we believe in personalized care for every patient. The Expanded Wharton’s Jelly Mesenchymal Stem Cells used in our treatments are sourced from carefully screened and ethically obtained umbilical cords. The treatment plan is customized to suit the specific needs of each individual, ensuring the most effective and personalized care possible.

Innovative and Safe Option:

WJ-MSC therapy represents an innovative and safe option for managing ALS. The procedure is minimally invasive, and WJ-MSCs have shown a favorable safety profile in clinical trials. Compared to traditional approaches, which mainly focus on symptom management, WJ-MSC therapy offers a potentially safer and more targeted solution.


The potential positive impact of Wharton’s Jelly Mesenchymal Stem Cells on ALS is an exciting avenue in regenerative medicine. At Regenamex, we are dedicated to advancing research and application of WJ-MSC therapy to offer hope and potential relief for patients facing the challenges of ALS. By leveraging the neuroprotective, regenerative, and anti-inflammatory properties of WJ-MSCs at a cellular level, we aim to provide improved motor function and an enhanced quality of life for patients living with ALS. Our experienced medical team is committed to delivering personalized and innovative care to bring hope and healing to those affected by this debilitating condition.

Fly & Buy HGH & TRT Program

Our programs offer a legal option that allows you to get the treatment you need for a fraction of the price in the US and Canada.